Replies to post #215181 on Biotech Values

[jbog]

NKTR:

A little nick in the armor this morning. Seems contained...


Phase III study with Amikacin Inhale in intubated and mechanically ventilated patients with Gram-negative pneumonia does not meet primary endpoint of superiority

PR Newswire PR NewswireNovember 24, 2017Comment

WHIPPANY, N.J., Nov. 24, 2017 /PRNewswire/ -- Bayer today announced that INHALE, a global Phase III clinical study program investigating Amikacin Inhale in addition to standard of care in intubated and mechanically ventilated patients with Gram-negative pneumonia, did not demonstrate superiority versus standard of care plus aerosolized placebo. The primary endpoint, as well as secondary endpoints were similar in both treatment arms, and were therefore not met. Amikacin Inhale is the development name of an integrated drug-device combination, consisting of a specially formulated Amikacin Inhalation Solution and a proprietary Synchronized Inhalation System with a vibrating mesh nebulizer.

[DewDiligence]

(NKTR)—The Opdivo + NKTR-214 trial in sarcoma is now listed:

https://www.clinicaltrials.gov/ct2/show/NCT03282344

If they see some durable responses in this patient population, we'll know NKTR-214 is the real deal.

[DewDiligence]

NKTR’s JPM Q&A session is 100% about NKTR-214. CEO, Howard Robin says (without hyperbole, IMO) that NKTR-214 is emerging as the centerpiece of the I-O industry.